NCT06523049尚未招募2 期
A Prospective, Multicenter, Phase II Clinical Trial of Vorolanib in Combination With Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Hao Zeng1 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2024年8月最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 67
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal. The primary endpoint is progression-free survival (PFS).
详细描述
This is a Phase II, multicenter, single-arm clinical trial designed to assess the efficacy and safety of Vorolanib in combination with Sintilimab in treating advanced renal cell carcinoma following the failure of prior immune checkpoint inhibitors based combination therapy. Participants will continue to receive Vorolanib and Sintilimab until disease progression, development of unacceptable toxic effects, death, or if the physician or patient decides to withdraw from the study. The primary endpoint is progression-free survival (PFS) according to RECIST v1.1 criteria as evaluated by the investigators.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years and ≤75 years, any gender.
- •Histologically confirmed diagnosis of renal cell carcinoma.
- •Diagnosis of metastatic renal cell carcinoma or TNM stage IV (according to the 2017 TNM staging system). Evidence of distant metastasis by imaging or pathology.
- •Prior immune checkpoint inhibitors based combination therapy, dual immune combination, or immune monotherapy with disease progression, or who have received second/third line targeted monotherapy, immune monotherapy, or a change in immune-based combination therapy after failure of one of the above therapies for no more than 1 month and have completed the washout period. ECOG performance status ≤
- •Life expectancy of at least 3 months.
- •Signed informed consent and ability to comply with the protocol-specified visits and procedures.
- •Agreement to provide tumor tissue and blood specimens required for the study.
- •Adequate organ and bone marrow function as follows: absolute neutrophil count (ANC) ≥1×10^9/L, platelets (PLT) ≥50×10^9/L, hemoglobin (HGB) ≥80g/L; liver function: serum total bilirubin (TBIL) ≤3 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤5 times ULN, serum albumin (ALB) ≥20 g/L; renal function: serum creatinine (Cr) ≤3×ULN.
排除标准
- •Pathologically diagnosed with non-renal cell carcinoma, collecting duct carcinoma.
- •First-line treatment with targeted monotherapy, or progression after first-line immune checkpoint inhibitors based combination therapy, followed by more than 1 month of treatment with targeted therapies, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-CTLA-4 antibodies specifically targeting T cell co-stimulation or checkpoint pathways and/or incomplete washout period.
- •Active brain metastases.
- •Personal history of other malignant tumors within 3 years with a different primary site or histology than that being evaluated in this study, excluding patients with well-controlled basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia.
- •Major surgery or severe trauma within 4 weeks prior to enrollment.
- •Subjects with conditions requiring systemic corticosteroids (>10mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days prior to initial study drug administration. Subjects with inactive autoimmune disease are allowed to receive local, ophthalmic, intra-articular, intranasal, inhaled corticosteroids, or adrenal replacement steroids (>10mg/day prednisone dose or equivalent).
- •Known or suspected active autoimmune disease (congenital or acquired), such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, thyroiditis, etc. Subjects with type 1 diabetes, thyroid dysfunction requiring only hormone replacement therapy, skin diseases (such as vitiligo, psoriasis, or alopecia) that do not require systemic treatment, or conditions expected not to recur in the absence of external triggering factors are allowed to participate in this study. Known allogeneic organ transplant (excluding corneal transplant) or allogeneic hematopoietic stem cell transplant.
- •Allergy to any component of monoclonal antibodies.
- •Uncontrolled other severe diseases, including but not limited to:
- •Severe infection in the active or poorly controlled clinical phase;
- •HIV infection (HIV antibody positive);
- •Acute or chronic active hepatitis B (HBsAg positive and HBV DNA >1*103/ml) or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA >15IU/ml);
- •Active pulmonary tuberculosis, etc.
- •NYHA class III-IV congestive heart failure, persistent symptomatic arrhythmia, uncontrolled atrial fibrillation; multiple echocardiographic assessments of left ventricular ejection fraction (LVEF) lower than the lower limit of normal.
- •Uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg);
- •Any arterial thrombosis, embolism, or ischemia in the past 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, etc.;
- •Diseases requiring warfarin (coumarin) anticoagulant therapy;
- •Uncontrolled hypercalcemia (calcium ion >1.5 mmol/L or calcium >12 mg/dL or corrected serum calcium >ULN), or symptomatic hypercalcemia requiring continued bisphosphonate therapy;
- •Uncontrolled adrenal insufficiency;
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months;
- •Severe, non-healing wounds or ulcers;
- •Gastrointestinal diseases with impaired gastrointestinal function (such as malabsorption, ulcerative disease, uncontrollable nausea, vomiting, diarrhea, or small bowel resection);
- •Other acute or chronic diseases, mental illnesses, or laboratory abnormalities that may lead to the following outcomes: increased risk associated with study participation or drug administration, or interference with interpretation of study results, and deemed ineligible for study participation at the discretion of the investigator;
- •Pregnant or lactating women.
研究组 & 干预措施
Combination treatment group
Experimental
Participants in this group will receive vorolanib tablets, 200 mg orally once daily, plus sintilimab injection, 200 mg intravenously every three weeks.
干预措施: Vorolanib Tablets (Drug)
Combination treatment group
Experimental
Participants in this group will receive vorolanib tablets, 200 mg orally once daily, plus sintilimab injection, 200 mg intravenously every three weeks.
干预措施: Sintilimab Injection (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: 3 years
Progression-free survival is assessed by investigators based on RECIST1.1, including disease progression or death from any cause.
次要结局
- Objective Response Rate (ORR)(3 years)
- Overall Survival (OS)(3 years)
- Adverse Events (AEs)(3 years)
- Disease Control Rate (DCR)(3 years)
- Duration of Response (DoR)(3 years)
- Quality of Life (QoL) assessed by FKSI-19(3 years)
- Quality of Life (QoL) assessed by EQ-5D-5L(3 years)
- Pain Score(3 years)
研究者
Hao Zeng
Professor
West China Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Metastatic Renal Cell CarcinomaNCT06284564M.D. Anderson Cancer Center10
暂停
2 期
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialAdvanced Renal Cell CarcinomaNCT05928806Michael B. Atkins, MD120
已完成
3 期
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)Renal Cell CarcinomaNCT01613846Technical University of Munich544
招募中
2 期
Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer SubjectsUrinary Bladder CancerNCT04861584Zhujiang Hospital41
已完成
2 期
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaRenal Cell CarcinomaNCT00423332AstraZeneca105